India’s first domestically produced HPV vaccine by SII to improve affordability, says GlobalData

The data and analytics company also noted that the National Technical Advisory Group on Immunisation recommended including HPV vaccination under the Universal Immunisation Programme (UIP) to the Union health ministry.

DGCI, Cervical cancer, SII, health news, pharma news, vaccines,
The government advisory panel NTAGI had recently also approved the qHPV after reviewing the clinical trial data of the vaccine.

Serum Institute of India’s (SII) Cervavac, a quadrivalent human papillomavirus (qHPV) vaccine is likely to be the first indigenous qHPV vaccine to be approved in India, according to GlobalData. According to GlobalData, this will not only make the drug more affordable to Indians but will also improve the overall penetration and address the growing number of cervical cancer cases in the country.

Experts emphasise that qHPV vaccines help protect against cancers caused by HPV such as cervical cancer. According to GlobalData’s Pharmaceutical Intelligence Center, the number of diagnosed prevalent cases of cervical cancer in India is estimated to grow at a compound annual growth rate (CAGR) of 3.11 percent, from 424,341 in 2021 to 540,435 in 2030.

“We are finally in sight of having an India-developed HPV vaccine! This will be a huge relief to the poorer members of our community who cannot afford the high price mark that comes with those offered by foreign manufacturers (approximately INR6,000–7,000 for a complete regimen). There are currently only two prophylactic HPV vaccines approved in India, and they are both manufactured abroad: Merck’s Gardasil (qHPV vaccine) and GSK’s Cervarix (bivalent HPV vaccine). Cervavac will be a welcome option,” Neha Myneni, Pharma Analyst at GlobalData said in a statement.

The data and analytics company also noted that the National Technical Advisory Group on Immunisation recommended including HPV vaccination under the Universal Immunisation Programme (UIP) to the Union health ministry. Although HPV vaccines were approved for inclusion in India’s UIP in 2017, they were not adopted nationally, mainly due to pricing concerns.

“Lack of inclusion in UIP means the benefits of these vaccines are not reaching the people in utmost need. This issue will likely be addressed once a domestic player like SII enters the HPV vaccination space. Cervavac is expected to be launched in November 2022,” Myneni stated.

Although, cervical cancer is the second most frequent among Indian women aged between 15 and 44 years, there is an extreme lack of awareness about this disease.

“Strategic initiatives from SII in the form of campaigns and support tools would help improve the general awareness of the disease among the target audience and strengthen the company’s market position. Moreover, the Union health ministry’s plans to launch a massive sensitization program to educate parents and school authorities about the significance of HPV vaccination are expected to boost SII’s vaccine uptake,” Myneni added.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In News Healthcare
Photos